

Macugen® (pegaptanib)

When requesting Macugen® (pegaptanib), the individual requiring treatment must be diagnosed with the following FDA-approved indication or the approved off-label compendial use and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indication

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Approved Off-Label Compendial Uses

- Other neovascular ophthalmic conditions (e.g., diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularization, choroidal neovascular conditions)

Coverage Guidelines

For all approved indications the individual must meet the following criteria for approval:

- Macugen is administered by or under the supervision of an ophthalmologist

Approval duration: 12 months

Dosing Recommendation

The recommended dose of Macugen is 0.3mg administered once every 6 weeks by intravitreal injection.

References

1. Macugen® injection [prescribing information]. Cedar Knolls, NJ: Eyetech Inc.; July 2016.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.